HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
TipRanks on MSN
HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for ...
The company notes the synthesized output is not intended to replace a standard 12-lead ECG. HeartBeam also plans to advance development of an on-demand 12-lead ECG extended wear monitor and build ...
An asymptomatic male patient with definite LQTS with a normal ECG and QTc who was flagged by the AI. Photo Credit: J. Martijn Bos and Michael Ackerman. A new artificial intelligence (AI) solution ...
Telemed Solutions, a cardiac device company, announced today the release of its initial product, the TM-12. The TM-12 is a PC-based wireless 12-Lead EKG system. It embeds a Bluetooth radio into an ECG ...
Artificial intelligence (AI) can detect signs of existing or emerging A-fib in ECGs that exhibit normal sinus rhythm, Mayo Clinic researchers have found. Their retrospective analysis, published online ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, ...
FDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome HeartBeam’s Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback